Assistance Publique Hopitaux De Paris

The Service de Cardiologie at Assistance Publique Hopitaux De Paris conducts studies aimed at improving outcomes for patients with cardiovascular disease and related risk factors.

• Dose optimization of combined cardiovascular agents
• Evaluation of heart‑failure endpoints in diabetic populations
• Blood‑pressure control strategies in hypertensive cohorts
• Safety profiling of novel metabolic‑cardiac therapies

Recent trials explore the impact of vicadrostat together with empagliflozin on reducing cardiovascular death, hospitalization for heart failure, and urgent visits in individuals with type 2 diabetes, hypertension and established disease.

Researchers in the cardiology department also lead investigations into neoplasms, focusing on melanoma subtypes that pose significant therapeutic challenges.

• Combination immunotherapy with checkpoint inhibitors
• Targeted therapy for NRAS‑mutated melanoma
• Assessment of progression‑free and overall survival
• Adaptive dose‑finding studies for novel agents

Key studies evaluate the efficacy of EIK1001 plus pembrolizumab and the pairing of naporafenib with trametinib in patients with advanced melanoma or unresectable or metastatic NRAS mutant cutaneous melanoma.